Inventiva S.A. (NASDAQ:IVA – Get Free Report) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 853,400 shares, an increase of 562.1% from the September 30th total of 128,900 shares. Based on an average daily volume of 201,000 shares, the short-interest ratio is presently 4.2 days.
Inventiva Stock Up 7.3 %
Shares of Inventiva stock traded up $0.18 on Friday, hitting $2.66. The company had a trading volume of 52,505 shares, compared to its average volume of 80,913. Inventiva has a twelve month low of $1.53 and a twelve month high of $4.75. The stock has a 50-day moving average of $2.21 and a 200-day moving average of $2.75.
Institutional Trading of Inventiva
A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC bought a new stake in Inventiva S.A. (NASDAQ:IVA – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 10,490 shares of the company’s stock, valued at approximately $38,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Inventiva Company Profile
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Featured Articles
- Five stocks we like better than Inventiva
- How to Calculate Inflation Rate
- Texas Roadhouse Stock Steering for New Highs This Year
- What Are Trending Stocks? Trending Stocks Explained
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.